https://doi.org/10.4081/monaldi.2022.2022

Role of IP-10 during follow up of pulmonary tuberculosis patients

Vol. 92 No. 4 (2022)
Submitted: July 20, 2021
Accepted: December 21, 2021
Published: January 27, 2022
Pulmonary Tuberculosis, IP-10, Follow up
Abstract Views: 1164
PDF: 552
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Himanshu Saini
Department of Pulmonary Medicine, Max Superspeciality hospital, Saket, New Delhi, India.
Parul Mrigpuri
parul57_mrigpuri@yahoo.com
Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India.
Balakrishnan Menon
Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India.
Sonal Sonal
Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, New Delhi, India.

Pulmonary tuberculosis (PTB) is an infectious disease caused by Mycobacterium tuberculosis (MTB) and is associated with significant mortality and morbidity. There has been a number of advances in the diagnosis of PTB but there is a need for simple blood based diagnostic test. A follow up of the patients on treatment remains challenging. This study was planned to evaluate the role of IP-10 in the follow up of PTB patients. A total of 60 subjects were enrolled in the study, 40 patients with confirmed diagnosis of PTB and 20 healthy controls. The value of interferon (IFN)γ inducible protein 10 (IP10) was measured in all the subjects at the start of the treatment and at a follow up of two months. Mean age of the study subjects was 40.96 years. Mean duration of symptoms at presentation was 1 month and 17 days. The induration on Tuberculin skin test (TST) was between 10-20mm in most (62.5%) of the study subjects. Majority (45%) showed moderately advanced disease on chest x-ray. There was no association of IP-10 with TST diameter and gene x-pert. Similarly, no significant difference in IP-10 levels was found in relation to sputum grading and x-ray score at diagnosis and after 2 months of treatment. IP-10 has very limited role in diagnosis of active TB in especially in high TB burden countries. The role of IP-10 in follow up of PTB patients could not be ascertained by our study. However, more studies are needed in this pretext with larger sample size and extended duration of follow up.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
World Health Organization. Global tuberculosis report 2020. Available from: https://www.who.int/publications/i/item/9789240013131
Khusro A, Aarti C, Salem AZM. An overview on the current status of tuberculosis and its biomarkers. J Biol Chemistry 2000;275:28326-31.
Nguyen TNA, Anton-Le Berre V, Bañuls A-L, Nguyen TVA. Molecular diagnosis of drug-resistant tuberculosis; A literature review. Front Microbiol 2019;10:794. DOI: https://doi.org/10.3389/fmicb.2019.00794
El-emiry FA, Attia GA, Ahmad AY, Sakr BM. Diagnostic value of inducible protein-10 in pulmonary tuberculosis. Egypt J Chest Dis Tubercul 2016;65:219-25. DOI: https://doi.org/10.1016/j.ejcdt.2015.08.012
Hong JY, Jung GS, Kim H, Kim YM, Lee HJ, Cho S-N, et al. Efficacy of inducible protein 10 as a biomarker for the diagnosis of tuberculosis. Int J Infect Dis 2012;16:e855-9. DOI: https://doi.org/10.1016/j.ijid.2012.07.013
Kabeer BSA, Raman B, Thomas A, et al.Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One 2010;5:e9051. DOI: https://doi.org/10.1371/journal.pone.0009051
Central TB Division, Directorate General of Health Services, Ministry of Health with Family Welfare. National strategic plan for tuberculosis elimination 2017-2025. Accessed: 2020 Jul 15. Available from: https://tbcindia.gov.in/WriteReadData/NSP%20Draft%2020.02.2017%201.pdf
World Health Organization. The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Available from: http://www.who.int/tb/publications/use-of-lf-lam-tb-hiv/en/
Ruhwald M, Aabye MG, Ravn P. IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev Mol Diagn 2012;12:175-87. DOI: https://doi.org/10.1586/erm.11.97
Dufour JH, Dziejman M, Liu MT, et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 2002;168:3195-204. DOI: https://doi.org/10.4049/jimmunol.168.7.3195
Lee J, Lee J-Y, Choi H-H, et al. Elevated levels of interferon-inducible protein10 (IP)-10/CXCL10, but not of interferon-γ, in patients with pulmonary tuberculosis. J Bacteriol Virol 2007;37:137-46. DOI: https://doi.org/10.4167/jbv.2007.37.3.137
Qiu X, Tang Y, Yue Y, et al. Accuracy of interferon-γ-induced protein 10 for diagnosing latent tuberculosis infection: a systematic review and meta-analysis. Clin Microbiol Infect 2019;25:667–72. DOI: https://doi.org/10.1016/j.cmi.2018.12.006
Qiu X, Xiong T, Su X, et al. Accumulate evidence for IP-10 in diagnosing pulmonary tuberculosis. BMC Infect Dis 2019;19:924. DOI: https://doi.org/10.1186/s12879-019-4466-5
Qiu X, Tang Y, Zou R, et al. Diagnostic accuracy of interferon-gamma-induced protein 10 for differentiating active tuberculosis from latent tuberculosis: A meta-analysis. Sci Rep 2019;9:11408. DOI: https://doi.org/10.1038/s41598-019-47923-w
Aabye MG, Ruhwald M, Praygod G, et al. Potential of interferon-γ-inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. Eur Respir J 2010;36:1488–90. DOI: https://doi.org/10.1183/09031936.00039010
Petrone L, Cannas A, Aloi F, Nsubuga M, Sserumkuma J, Nazziwa RA, et al. Blood or urine IP-10 cannot discriminate between active tuberculosis and respiratory diseases different from tuberculosis in children. Biomed Res Int 2015;2015:589471. DOI: https://doi.org/10.1155/2015/589471
Whittaker E, Gordon A, Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma? PLoS One 2008;3:e3901. DOI: https://doi.org/10.1371/journal.pone.0003901
Tonby K, Ruhwald M, Kvale D, Dyrhol-Riise AM. IP-10 measured by dry plasma spots as biomarker for therapy responses in Mycobacterium tuberculosis infection. Sci Rep 2015;5:9223. DOI: https://doi.org/10.1038/srep09223
Azzurri A, Sow OY, Amedei A, et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005;7:1–8. DOI: https://doi.org/10.1016/j.micinf.2004.09.004
Wergeland I, Pullar N, Assmus J, et al. IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. J Infect 2015;70:381-91. DOI: https://doi.org/10.1016/j.jinf.2014.12.019
Kobashi Y, MouriK, Kato S, Oka M. Clinical evaluation of IP-10 and MIG for the diagnosis of active tuberculosis disease. Mycobact Dis 2015;5:1000185. DOI: https://doi.org/10.4172/2161-1068.1000185
Jeong YH, Hur Y-G, Lee H, et al. Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production. J Clin Microbiol 2015;53:504–10. DOI: https://doi.org/10.1128/JCM.02758-14

How to Cite

Saini, Himanshu, Parul Mrigpuri, Balakrishnan Menon, and Sonal Sonal. 2022. “Role of IP-10 During Follow up of Pulmonary Tuberculosis Patients”. Monaldi Archives for Chest Disease 92 (4). https://doi.org/10.4081/monaldi.2022.2022.
Copyright (c) 2022 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.